Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
about
The Prodrug Approach: A Successful Tool for Improving Drug SolubilityRecent developments in adenosine receptor ligands and their potential as novel drugsPhase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactionsPotential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein.Bioavailability challenges associated with development of anti-cancer phenolics.Xanthines as adenosine receptor antagonists.GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs?Prodrugs for improving tumor targetability and efficiency.Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin AProgrammed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein 7.Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.In vitro-in vivo correlation of efavirenz tablets using GastroPlus®Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs.The future of prodrugs - design by quantum mechanics methods.Prodrugs design based on inter- and intramolecular chemical processes.Using predrugs to optimize drug candidates.Pharmacokinetic study and bioavailability of a novel synthetic trioxane antimalarial compound 97/63 in rats.Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A2A receptor.Solubility and dissolution enhancement strategies: current understanding and recent trends.Design, synthesis, and in vitro kinetics study of atenolol prodrugs for the use in aqueous formulations.Prodrug ionic liquids: functionalizing neutral active pharmaceutical ingredients to take advantage of the ionic liquid form
P2860
Q26771271-56B2DB42-450B-4F05-AA7B-A4413198119CQ27687253-060456A7-D51C-414C-8D3A-0A9A94498E85Q33597447-58FC8CFE-403D-4048-882F-BFCCF132F1D2Q33775959-62A3EBB0-F736-4356-86AD-FDE629D050D0Q34002451-FF1EAA29-F5A5-4787-9AA7-150BBFA21AC5Q34057398-12821584-9B78-4CB6-8F29-21ADEA91AA01Q34139398-962D1044-2881-4E2C-A8C4-6737B6417FD4Q34548745-4D425565-0440-4DF2-962A-1B8EC43E3C8EQ35095165-BDC5FB4D-3BDA-4A0E-AD8C-95198F851B01Q35667995-C961DD0E-4502-4D16-AB84-55593A6E8BF3Q35844437-C0E83190-575C-45D9-947E-9647E6E392FDQ36342362-F2C7F47C-2D0A-4BDB-B3D3-B3408B3FC5ECQ36716649-29E82F9E-17FB-481A-ADDD-F89A1C6D5769Q37126427-5D64B890-9DEA-4D34-BCB9-A942C81D1DF1Q37560375-F35686C1-409C-496B-826B-44CF984441E5Q38068081-1B74FE60-10BD-4A04-9CAC-66DE0CF71820Q38075544-B4726C40-6D9E-4AA2-B776-2FF9224450B9Q38094262-42162F6D-5F0C-44FA-811A-AE0B9DE34173Q38133663-28879CE8-4F62-4A1B-9629-8EBBDBE7459FQ38243993-6A2E1E98-3853-44F4-B35F-162406E81614Q41886531-605EE54A-2C12-4BD7-92AB-E8199C5000DDQ50917169-FC9C5DF6-8FE1-4E2F-854B-E832FD153C70Q51020710-03F7950C-4E45-4349-A412-9137F432766BQ53066562-B18E79DF-05D4-4FF8-8CE1-78813D2355ABQ57087031-A1D08D7F-BBD8-445C-87C9-B5FBE071BEAB
P2860
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@ast
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@en
type
label
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@ast
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@en
prefLabel
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@ast
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@en
P356
P1476
Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
@en
P304
P356
10.1002/CBDV.200900114
P577
2009-11-01T00:00:00Z